Winship Cancer Institute of Emory University | Strategic Alliance Partners

March 01, 2024

Reshma Jagsi, MD, Dphil, discusses caveats when interpreting long-term results from the IDEA trial of radiotherapy omission in breast cancer.

March 01, 2024

Jane L. Meisel, MD, shares information from a study that evaluated patient-reported perceptions of patient-provider communication in breast cancer care.

February 29, 2024

Susan C. Modesitt, MD, FACOG, FACS, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

February 26, 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

February 22, 2024

Reshma Jagsi, MD, DPhil, discusses 5-year findings from the IDEA trial assessing radiotherapy omission for postmenopausal patients with breast cancer.

February 21, 2024

Jonathon B. Cohen, MD, MS, discusses treatment considerations for mantle cell lymphoma and the role of pirtobrutinib in the management of this disease.

February 21, 2024

The S1706 study is currently enrolling patients with inflammatory breast cancer to determine if adding a PARP inhibitor to radiation therapy is effective.

February 20, 2024

Jane L. Meisel, MD, discusses patient-reported perceptions of patient-provider communication in cancer care.

February 19, 2024

Following chemoradiation, maintenance osimertinib improved PFS vs placebo in patients with stage III EGFR-mutant non–small cell lung cancer.

February 16, 2024

Investigating when radiation therapy can be appropriately omitted and striving to uncover disparities are areas of focus in the field of radiation oncology.

February 14, 2024

Jonathon B. Cohen, MD, MS, discusses the background of the BRUIN study of pirtobrutinib in previously treated patients with mantle cell lymphoma.

February 07, 2024

Jane L. Meisel, MD, discusses the rationale for evaluating communication challenges that currently exist between patients and their oncologists.

February 06, 2024

Drs Mayer and Kalinsky conclude their discussion with a look at agents in development and unmet needs for patients with breast cancer and ESR1 mutations.

February 03, 2024

Ticiana Leal, MD, discusses the variety of DLL3-targeted agents in development for patients with small cell lung cancer and neuroendocrine tumors.

February 02, 2024

Jonathon B. Cohen, MD, MS, expands on updated data from the BRUIN trial of pirtobrutinib in patients with relapsed BTK-exposed mantle cell lymphoma.

February 02, 2024

Sagar Lonial, MD, FACP, details how CAR T-cell therapies and off-the-shelf treatments are improving outcomes for patients with multiple myeloma.

January 30, 2024

Medical oncologists discuss oral SERDs, with a focus on the SERENA-2 trial looking at camizestrant in patients with advanced ER+/HER2- breast cancer.

January 30, 2024

Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.

January 23, 2024

Kevin Kalinsky, MD, MS, gives an overview of recent data from the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer.

January 23, 2024

Drs Mayer and Kalinsky provide insights and offer their impressions of the PADA-1 trial, focusing on ESR1 mutation monitoring with circulating tumor DNA (ctDNA).